Thursday 02 May 2024
Internal Reference Number: FOI_7296
Date Request Received: 11/07/2023 00:00:00
Date Request Replied To: 02/08/2023 00:00:00
This response was sent via: By Email
Request Summary: Oesophageal and Gastric Cancer
Request Category: Companies
| Question Number 1: How many patients were treated in the past 3 months for gastric and gastro-oesophageal junction cancer (any stage) with: • CAPOX (Capecitabine with Oxaliplatin) • FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin) • Lonsurf (Trifluridine - tipiracil) • Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) • Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) • Any other systemic anti-cancer therapy • Palliative care only | |
| Answer To Question 1: • CAPOX (Capecitabine with Oxaliplatin) <5 • FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin) 0 • Lonsurf (Trifluridine - tipiracil) 0 • Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) 0 • Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) 0 • Any other systemic anti-cancer therapy <5 • Palliative care only unable to answer | |
| Question Number 2: How many patients were treated in the past 3 months for Oesophageal cancer (any stage) with: • Nivolumab monotherapy or combination with Ipilimumab • Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidene (5-Fluorouracil or Capecitabine) • Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidene (5-Fluorouracil or Capecitabine) • Platinum and Fluoropyrimidene based combination treatments (Cisplatin or Oxaliplatin with 5-Fluorouracil or Capecitabine) • Any other systemic anti-cancer therapy • Palliative care only | |
| Answer To Question 2: • Nivolumab monotherapy or combination with Ipilimumab 1 • Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidene (5-Fluorouracil or Capecitabine) 0 • Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidene (5-Fluorouracil or Capecitabine) 0 • Platinum and Fluoropyrimidene based combination treatments (Cisplatin or Oxaliplatin with 5-Fluorouracil or Capecitabine) <5 • Any other systemic anti-cancer therapy <5 • Palliative care only unable to answer | |
| Question Number 3: How many patients were treated in the past 3 months for advanced/metastatic resected oesophageal cancer ONLY with: • Nivolumab monotherapy or combination with Ipilimumab • Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidene (5-Fluorouracil or Capecitabine) • Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidene (5-Fluorouracil or Capecitabine) • Platinum and Fluoropyrimidene based combination treatments (Cisplatin or Oxaliplatin with 5-Fluorouracil or Capecitabine) • Any other systemic anti-cancer therapy • Palliative care only | |
| Answer To Question 3: Nivolumab monotherapy or combination with Ipilimumab 0 • Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidene (5-Fluorouracil or Capecitabine) 0 • Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidene (5-Fluorouracil or Capecitabine) 0 • Platinum and Fluoropyrimidene based combination treatments (Cisplatin or Oxaliplatin with 5-Fluorouracil or Capecitabine) 0 • Any other systemic anti-cancer therapy <5 Palliative care only unable to answer | |
| Question Number 4: In the past 3 months, how many patients have been initiated* on the following agents for treatment for gastric, gastro-oesophageal junction or Oesophageal cancer: • Nivolumab monotherapy or in combination with Ipilimumab • Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidene (5-Fluorouracil or Capecitabine) • Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidene (5-Fluorouracil or Capecitabine) *Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen. | |
| Answer To Question 4: • Nivolumab monotherapy or in combination with Ipilimumab <5 • Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidene (5-Fluorouracil or Capecitabine) 0 • Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidene (5-Fluorouracil or Capecitabine) 0 *Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen. | |
| Question Number 5: Does your trust participate in any clinical trials for gastric cancer? If so, please provide the name of each trial and the number of patients taking part. | |
| Answer To Question 5: The Trust is not currently participating in any clinical trials for gastric cancer. | |
| Question Number 6: Does your trust participate in any clinical trials for oesophageal cancer? If so, please provide the name of each trial and the number of patients taking part. | |
| Answer To Question 6: The Trust is not currently participating in any clinical trials for oesophageal cancer. | |
| To return to the list of all the FOI requests please click here |
Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
